clinical trial · NCT04754100
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple MyelomaagenT-797
brief summary
This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.
started
Mar 29, 2021
primary completion
Jan 13, 2023
completion
May 31, 2023
last updated
Jun 6, 2023
official title
A Phase 1, Open-Label Study of the Safety, Tolerability, and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) in Subjects With Relapsed/Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol